Latest information on COVID-19
Support teaching, research, and patient care.
Gastroenterology, biliary motility, hormonal regulation, embryology, gastrointestinal tract, clinical management of pediatric liver transplant recipients.
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Not Recruiting
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
Stanford is currently not accepting patients for this trial. For more information, please contact Ken Cox, MD, 650-721-2250.
View full details
Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Not Recruiting
The goals of the proposed work are two fold: Firstly, to see if the antibiotic vancomycin may be used for the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC). The investigators hope to learn what effect Vancomycin has on the bacteria that are present in stool, body fluid or intestinal tissue on someone who has BA and PSC and if so by what mechanism. Secondly, the investigators hope to learn to characterize human intestinal microbial communities (microbiome: the collection or collectivity of microorganisms) using molecular methods, examine the mechanisms of interaction between host and microbiome using genomic approaches, and determine how the microbiome both preserves local health and promotes pathology. The investigators will focus on primary sclerosing cholangitis, biliary atresia, as well as states of health. The composition of the associated microbiome will be assessed based on ribosomal DNA and RNA sequences, and attention will be given to richness (diversity), evenness (relative abundance), and variation with respect to time, person, and anatomic niche. Host response at the adjacent mucosal surface will be assessed based on genome-wide gene expression patterns.
Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
A Study of Oral Hymecromone and Hyaluronan Synthesis Not Recruiting
The purpose of this study is to add further understanding to the doses of hymecromone that effectively and safely lead to the inhibition of hyaluronan synthesis. In this study we will investigate both circulating hyaluronan in the serum, as well as tissue hyaluronan, using sputum samples as a non-invasive surrogate. This is a parallel, open-label, single-center, dose-response study of hymecromone in healthy adults 18 years of age or older. Up to 18 participants will be enrolled. Participants will be treated for 4 days with study drug. Safety as well as biomarkers of pharmacokinetic and pharmacodynamic response will be monitored during therapy.
Stanford is currently not accepting patients for this trial. For more information, please contact Adam Frymoyer, MD, .
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease Not Recruiting
This study investigates whether the specific carbohydrate diet (SCD) can maintain clinical remission in pediatric and adult patients with Crohn's disease.
Stanford is currently not accepting patients for this trial. For more information, please contact Ken Cox, MD, (650) 721-2250.
